Comparing Research Compounds

Published August 21, 2026 · Artemis Labs

Research Buyer FAQ › Comparing Research Compounds

This page is a map, not the destination. Each answer says in a few sentences how two compounds differ in class and structure, then sends you to the full comparison or to the two product pages, where the citations live. Nothing here describes an outcome in a person. All material is supplied for laboratory research use only.

How this page was built. Comparisons here are structural — sequence origin, receptor family, composition. Sequence, CAS and receptor citations sit in the References section of each linked page.


BPC-157 vs TB-500 — what is the difference?

They are different molecules from different origins. BPC-157 is a synthetic sequence derived from a protein found in gastric juice. TB-500 is a fragment of thymosin beta-4, a protein found in many tissues. Different parent molecules, different pathways in the published tissue-repair work. The side-by-side is BPC-157 versus TB-500.

Is TB-500 the same as thymosin beta-4?

Related, not identical. Thymosin beta-4 is a 43-residue protein found in many tissues. TB-500 is a synthetic peptide reproducing one segment of it — the actin-binding region — a fragment, not the full molecule. The published record on thymosin beta-4 includes findings that cut against it (Sun 2025, PMID 41278163), noted on TB-500.

Retatrutide vs tirzepatide — what is the difference?

Receptor count. Tirzepatide is described in the literature as binding two receptors, GIP and GLP-1. Retatrutide is described as binding three, adding the glucagon receptor. That structural difference is what separates them. The full comparison, with sequences and citations, is tirzepatide versus retatrutide.

Cagrilintide vs retatrutide and tirzepatide — what is the difference?

Different hormone systems. Tirzepatide and retatrutide are incretin-receptor multi-agonists — tirzepatide described as binding the GIP and GLP-1 receptors, retatrutide adding the glucagon receptor. Cagrilintide is a long-acting analog of amylin, a different pancreatic hormone, and is not an incretin agonist. Compare Cagrilintide, and the pair in tirzepatide versus retatrutide.

CJC-1295 vs sermorelin — what is the difference?

Both act at the same receptor; they differ in structure and how long they survive. Sermorelin is GHRH(1-29), the first 29 residues of natural growth-hormone-releasing hormone. CJC-1295 is a modified analog of that sequence, built to resist breakdown for longer. The detail is in CJC-1295 versus sermorelin.

CJC-1295 with DAC vs without DAC — what is the difference?

One structural addition separates them. CJC-1295 with DAC carries a Drug Affinity Complex — a chemical group that binds serum albumin, described in the published record as extending how long the peptide survives in circulation. Without DAC, the underlying modified GHRH(1-29) sequence remains, minus that group. Artemis Labs stocks the DAC form: CJC-1295 DAC. Background: CJC-1295 versus sermorelin.

Semax vs Selank — what is the difference?

They are unrelated sequences that share a research origin. Both came out of Russian institutes, and both are short peptides. Semax is an analog of the ACTH(4-10) fragment. Selank is an analog of tuftsin, a small immune peptide. Different parent molecules, different literatures. Compare Semax and Selank.

Sermorelin vs CJC-1295 vs ipamorelin — what is the difference?

It is two families, not three variants. Sermorelin and CJC-1295 are both GHRH analogs and act at the GHRH receptor. Ipamorelin is not a GHRH analog at all — it acts at the ghrelin receptor, a separate target. The GHRH pair is compared in CJC-1295 versus sermorelin.

Ipamorelin vs sermorelin — what is the difference?

Two different receptor families. Sermorelin is a GHRH analog — the first 29 residues of growth-hormone-releasing hormone — and acts at the GHRH receptor. Ipamorelin is a five-residue peptide that acts at the ghrelin receptor, a separate target. That receptor difference is the whole distinction that belongs here. Compare Ipamorelin and Sermorelin.

Ipamorelin vs tesamorelin — what is the difference?

The same family contrast at a different length. Ipamorelin acts at the ghrelin receptor. Tesamorelin is a GHRH analog — the full GHRH(1-44) sequence with a stabilising group attached — and acts at the GHRH receptor. Two receptor families, not two versions of one molecule. Compare Ipamorelin and Tesamorelin.

CJC-1295 vs tesamorelin — what is the difference?

Two GHRH analogs, two stabilisation strategies. CJC-1295 modifies the shorter GHRH(1-29) sequence and, in its DAC form, adds an albumin-binding group. Tesamorelin keeps the full GHRH(1-44) sequence with a hexenoyl group attached at one end. Same receptor family, different molecules. Compare CJC-1295 DAC and Tesamorelin.

What is the difference between GLOW and KLOW?

KLOW is GLOW with a fourth component. GLOW contains GHK-Cu, BPC-157 and TB-500. KLOW contains those three plus KPV. Everything else about the two vials follows from that single difference. Component amounts per sealed vial and CAS numbers are listed on GLOW and KLOW.

Tesamorelin vs sermorelin — what is the difference?

Length and modification. Both are GHRH analogs. Sermorelin is GHRH(1-29), the natural fragment. Tesamorelin is based on the longer GHRH(1-44) sequence with a chemical group attached at one end to slow its breakdown. Same receptor family, different molecules. Compare Tesamorelin and Sermorelin.

PT-141 vs Melanotan-2 — what is the difference?

Receptor selectivity, and nothing else belongs in this answer. Melanotan-2 binds across the melanocortin receptor family — MC1R, MC3R, MC4R and MC5R. PT-141, also called bremelanotide, is a related molecule with a preference for MC4R. Compare PT-141 and Melanotan-2 for the receptor selectivity detail.


Melanotan-1 vs Melanotan-2 — what is the difference?

Structure and receptor breadth. Both are synthetic analogs of alpha-MSH. Melanotan-1 is a linear analog described in the literature as selective for the MC1 receptor. Melanotan-2 is a shorter, cyclic analog that binds across the melanocortin receptor family — MC1R, MC3R, MC4R and MC5R. Receptor selectivity is the whole distinction. We stock Melanotan-2.

SLU-PP-332 vs MOTS-c — what is the difference?

Different molecule classes entirely. MOTS-c is a peptide encoded inside mitochondrial DNA, so cells make it themselves. SLU-PP-332 is not a peptide — it is a synthetic small molecule described in the literature as an agonist of the estrogen-related receptors (ERRs). A peptide and a small molecule, not two peptides. Compare SLU-PP-332 and MOTS-c.

KPV vs BPC-157 — what is the difference?

Size and origin. KPV is a three-residue peptide — the final segment of alpha-MSH, a natural signalling hormone. BPC-157 is a fifteen-residue synthetic sequence derived from a protein found in gastric juice. Different parent molecules, different receptor literatures, no overlap in sequence. Compare KPV and BPC-157.

Cartalax vs GHK-Cu — what is the difference?

Both are short peptides; the resemblance ends there. Cartalax is a short synthetic peptide from the Russian bioregulator research line. GHK-Cu is a naturally occurring tripeptide that binds a copper(II) ion — the copper complex is why its vials are blue. Different sequences, different origins, different literatures. Compare Cartalax and GHK-Cu.

NAD+ vs its precursors (NR, NMN) — what is the difference?

NAD+ is not a peptide — it is a coenzyme, a small molecule cells use in energy metabolism. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors: earlier steps on the route cells use to build NAD+. Three points on one pathway, not three versions of one thing. See NAD+; classification is covered under are all research peptides actually peptides.

This page is one section of the full Artemis Labs research-buyer FAQ.

References

Sequence origins, CAS numbers and receptor citations for each compound sit in the References section of its product page and of the comparison guide linked beside it:

  1. BPC-157 versus TB-500 — tissue-repair comparison
  2. Tirzepatide versus retatrutide
  3. CJC-1295 versus sermorelin — GHRH comparison
  4. GLP-1 receptor agonism explained